Nifukang, an IgA nephropathy drug owned by Genting Xinyao up nearly 27%, will be approved in the fourth quarter.

[Genting Xinyao's IgA nephropathy drug Nafukang will be approved in the fourth quarter] as of press time, Genting Xinyao (01952.HK) is up 26.90%. In terms of news, Genting Xinyao's drug Nefecon (Nifukang) is the first drug approved for the treatment of IgA in 50 years, and it is currently the only drug for IgA nephropathy in the world. Genting Xinyao said that Nafukang products are undergoing NDA approval in China as planned and are expected to be approved in the fourth quarter.